Results 11 to 20 of about 16,304 (256)
Arthritis Research & Therapy, 2020 Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated.
Mark C. Genovese +9 more
doaj +1 more source
Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients
Therapeutic Advances in Gastroenterology, 2021 Background: In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients.
Karoline Soares Garcia +8 more
doaj +1 more source
Rheumatology International, 2014 Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Nathalia Galli +4 more
openaire +3 more sources
Potential Cost-Savings From the Use of the Biosimilars in Slovakia
Frontiers in Public Health, 2020 Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate the potential cost-savings from the use of biosimilars in Slovakia based on two different data sources.Methods: National reimbursement lists from the Czech Republic ...
Tomas Tesar +6 more
doaj +1 more source
Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
Pharmaceuticals, 2021 Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
Manuel García-Goñi +3 more
doaj +1 more source
Physicians’ perceptions of the uptake of biosimilars: a systematic review
BMJ Open, 2020 Objectives To examine physicians’ perceptions of the uptake of biosimilars.Design Systematic review.Data sources MedLine Ovid and Scopus databases at the end of 2018.Eligibility criteria Original scientific studies written in English that addressed ...
Katri Hämeen-Anttila +3 more
doaj +1 more source
Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption
Medicina, 2022 (1) Background: A biosimilar is a biologic medical product that has been approved by the United States Food and Federal Drug Administration (FDA) and is an almost identical copy of an original biologic product yet manufactured by a different company ...
John Hair +2 more
doaj +1 more source
JCO Global Oncology, 2021 PURPOSEBreast cancer is the most common malignancy in Brazilian women, with 66,280 new cases in 2020 (with 20% overexpressing human epidermal growth factor receptor 2 [HER2]).
Heloísa M. Resende +7 more
doaj +1 more source
Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective [PDF]
Global Journal on Quality and Safety in Healthcare, 2020 Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients.
Mansoor A. Khan +4 more
doaj +1 more source
Switching Among Biosimilars: A Review of Clinical Evidence
Frontiers in Pharmacology, 2022 Biological medicines have improved patients’ outcomes, but their high costs may limit access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality, safety, and efficacy to an already licensed originator biological product,
Eleonora Allocati +6 more
doaj +1 more source